张振雷-pg电子游戏试玩平台网站
pg电子游戏试玩平台网站
pg电子游戏试玩平台网站

张振雷-pg电子游戏试玩平台网站

微信/qq扫一扫转发

您所在的位置:pg电子pg电子官网首页  师资队伍  师资队伍  张振雷

点击数:554 来源:化学与药学学院 作者: 录入:化学与药学学院 更新时间:2022-05-18

pg电子官网的联系方式

手机号码:13026930224

电子邮箱:zhangzl@mailbox.gxnu.edu.cn

办公地址:重点实验室2号楼2403

研究方向

1. 功能化抗肿瘤金属化合物

2. 蛋白质导向的药物设计

学历背景

2014-2020 广西师范大学化学与药学学院 (硕,博)

工作经历

2021.1-至今,省部共建药用资源化学与药物分子工程国家重点实验室,专职科研岗,讲师,硕导

代表性论文

(*通讯作者, #共同第一作者)

11. zhang zl#, zhang jz#, yang tf#, li sh, xu g, liang h*, yang f*. developing an anticancer platinum(ii) compound based on the uniqueness of human serum albumin. journal of medicinal chemistry, 2023, 66: 5669–5684. (医学1区, if=8.039)

10. yang tf#, zhang zl#, zhang jz#, li yp, li wj, liang h*, yang f*. developing a gallium(iii) agent based on properties of the tumor micro-environment and lactoferrin: achieving two-agent co-delivery and multi-targeted combination therapy of cancer. journal of medicinal chemistry, 2023, 66: 793−803. (医学1区, if=8.039)

9. zhang zl#, yang tf#, zhang jz#, li wj, li sh, sun hb, liang h*, yang f*. developing a novel indium(iii) agent based on human serum albumin nanoparticles: integrating bioimaging and therapy. journal of medicinal chemistry, 2022, 65: 5392−5406. (医学1区, if=8.039) 

8. yang tf, zhu mh, jiang m, yang f, zhang zl*. current status of iridium-based complexes against lung cancer. frontiers in pharmacology, 2022, 13: 1025544. (医学2区, if=5.988)

7. zhang jz#, zhang zl#, jiang m, li sh, yuan hl, sun hb, yang f*, liang h*. developing a novel gold(iii) agent to treat glioma based onthe unique properties of apoferritin nanoparticles: inducing lethal autophagy and apoptosis. journal of medicinal chemistry, 2020, 63: 13695−13708. (医学1区, if=8.039)

6. zhang zl, zhang jz, jiang m,zhao l, li sh, sun hb, yang f*, liang h*. human serum albumin-based dual-agent delivery systems for combination therapy: acting against cancer cells and inhibiting neovascularization in the tumor microenvironment. molecular pharmaceutics, 2020, 17: 1405−1414. (医学2区, if=5.364, 被选为期刊封面论文)

5. zhang zl#, yu p#, gou y, zhang jz, li sh, cai ml, sun hb, yang f*, liang h*. novel brain-tumor-inhibiting copper(ii) compound based on a human serum albumin (hsa)-cell penetrating peptide conjugate. journal of medicinal chemistry, 2019, 62: 10630−10644. (医学1区, if=8.039)

4. gou y#, zhang zl#, li dy#, zhao l, cai ml, sun zw, li y, zhang y, khan h, sun h, wang t, liang h*, yang f*. hsa-based multi-target combination therapy: regulating drugs' release from hsa and overcoming single drug resistance in a breast cancer model. drug delivery, 2018, 25: 321−329. (医学2区, if=6.819)

3. wang j#, gou y#, zhang zl#, yu p, qi jx, qin qp, sun hb, wu xy, liang h, yang f*. developing an anticancer copper(ii) multitarget pro-drug based on the his146 residue in the ib subdomain of modified human serum albumin. molecular pharmaceutics, 2018, 15: 2180−2193. (医学2区, if=5.364)

2. zhang y#, zhang zl#, gou y, jiang m, khan h, zhou zp*, liang h*, yang f*. design an anticancer copper(ii) pro-drug based on the flexible iia subdomain of human serum albumin. journal of inorganic biochemistry, 2017, 172: 1–8. (生物学2区, if=4.336).

1. zhang zl#,gou y#, wang j#, qi jx, zhang y, liang sc*, liang h*, yang f*. four copper (ii) compounds synthesized by anion regulation: structure, anticancer function andanticancer mechanism. european journal of medicinal chemistry, 2016, 121: 399−409.(医学1区, if=7.088)

科研项目

(1) 广西科学自然基金-青年项目:基于脱铁铁蛋白特性发展诊疗一体化抗肿瘤先导金属化合物,8万元。(2022.04-2025.03)

(2) 省部共建药用资源化学与药物分子工程国家重点实验室人才引进课题:基于内源性蛋白特性发展诊疗一体化金属药物,50万元。(2021.05-2024.05)


网站地图